Small but Mighty, ECAN turns 12
Twelve years ago, a small but mighty group of dedicated folks who wanted to see significant change for patients [...]
Three New Immunotherapy Indications for Esophageal Cancer Patients
Since March 2021, the U.S. Food and Drug Administration has issued four approvals for PD-L1 Inhibitors for patients with Esophageal [...]
A Reason for Optimism
This is the 13th anniversary of my husband's death. It may sound like a contradiction, but it is a reason [...]
ECAN Experts cited in US News & World Report
"Esophageal Cancer: What to Know" is a new report from U.S. News & World Report by contributing writer David Levine. [...]
FDA Fast-Tracks Review of 3 New Immunotherapy Options for Esophageal Cancer Patients
The U.S. Food & Drug Administration has granted Priority Review for the use of immunotherapies in three new designations for [...]
New Treatment Option for Patients with HER2+ Gastroesophageal Junction Adenocarcinoma
The U.S. Food & Drug Administration has approved a new therapy for adult patients with locally advanced or metastatic HER2+ [...]
Latest US Stats Show More Esophageal Cancer Cases, Fewer Deaths
The latest statistics released by the American Cancer Society projects that fewer Americans will die of Esophageal Cancer in 2021 [...]
Hope is Important
These are challenging times. And we at ECAN are keeping our focus trained on the positive difference we can [...]
2020 Wins for Esophageal Cancer Patients
Despite the challenges of 2020, progress was achieved in the battle to end Esophageal Cancer - much of it thanks [...]
Make It A Life-Saving Birthday
In May of 2010, Brent Sharpless was in the prime of his life. He was an active, healthy 36-year-old who [...]